Skip to main content
SpringerLink
Log in

The use of inhaled corticosteroids in children with asthma

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

The inhaled corticosteroids (ICSs) are the most effective long-term controllers for the treatment of childhood asthma. There is now substantial controlled clinical trial data to support the efficacy and safety of ICS therapy in infants and young children (6 months to 4 years of age). These data support the use of nebulizer suspension or metered-dose inhalers with valved holding chambers as effective forms of delivery in this age group. Currently, selection of delivery method depends on the comfort of the parent and the cooperation of the child, as well as on which drug the clinician chooses. The ICSs have a favorable safety profile when administered in currently recommended dosages. A transient 0.5- to 2-cm growth delay occurs in prepubescent children but does not appear to affect attainment of predicted adult height. Long-term trials support the existing recommendations of lowering dosage once control is achieved and stopping therapy when the child’s asthma is in remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program, Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services; 1997. [NIH publication no. 97-4051.]

    Google Scholar 

  2. Centers for Disease Control and Prevention: Measuring childhood asthma prevalence before and after the 1997 redesign of the National Health Interview Survey—United States. MMWR Morb Mortal Wkly Rep 2000, 49:908–911.

    Google Scholar 

  3. Weiss KB, Sullivan SD: The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001, 107:3–8.

    Article  PubMed  CAS  Google Scholar 

  4. National Heart, Lung, and Blood Institute: Global Initiatives for Asthma (GINA). Pocket guide for asthma management and prevention. Bethesda, MD: US Department of Health and Human Services; 1998. [NIH publication no. 96-3659B.]

    Google Scholar 

  5. Goodman DC, Lozano P, Stukel TA, et al.: Has asthma medication use in children become more frequent, more appropriate, or both. Pediatrics 1999, 104:187–194.

    Article  PubMed  CAS  Google Scholar 

  6. Janson C, Chinn S, Jarvis D, Burney P: Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997, 10:1795–1802.

    Article  PubMed  CAS  Google Scholar 

  7. Suissa S, Ernst P, Benayoun S, et al.: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 343:332–336.

    Article  PubMed  CAS  Google Scholar 

  8. Donahue JG, Weiss ST, Livingston JM, et al.: Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997, 277:887–891.

    Article  PubMed  CAS  Google Scholar 

  9. Adams RJ, Fuhlbrigge A, Finkelstein JA, et al.: Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 2001, 107:706–711.

    Article  PubMed  CAS  Google Scholar 

  10. The Childhood Asthma Management Program Research Group: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054–1063. This is the longest, most extensive study of ICS therapy in children with asthma to date. It explored the ability of ICS therapy to improve lung growth in children with mild to moderate asthma. Children aged 5 to 12 years old (n=1041) were randomized to budesonide, nedocromil, or placebo and followed for 4 to 6 years (mean 4.3 years). While there was no difference in lung growth among the three treatments, budesonide therapy reduced airway hyperresponsiveness, as-needed prednisone use, and health resource utilization compared with placebo. The only adverse effect was a transient decrease in growth velocity in the first year that did not persist throughout the study.

    Article  Google Scholar 

  11. Szefler SJ: Challenges in assessing outcomes for pediatric asthma. J Allergy Clin Immunol 2001, 107:S456-S464.

    Article  PubMed  CAS  Google Scholar 

  12. Baker JW, Mellon M, Wald J, et al.: A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999, 102:414–421. A double-blind, placebo-controlled trial of budesonide inhalation suspension in 480 asthmatic children 6 months to 8 years old with moderate to severe disease. This study evaluated four different doses of the drug and showed that the lowest dose of 0.25 mg once daily did not lower symptom scores greater than placebo but that all other doses (0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily) were significantly better than placebo. This was one of the pivotal trials to gain US Food and Drug Administration approval for this drug and the only approved ICS for children less than 4 years of age.

    Article  Google Scholar 

  13. Kemp JP, Skoner D, Szefler SJ, et al.: Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999, 83:231–239.

    Article  PubMed  CAS  Google Scholar 

  14. Connett GJ, Warde C, Wooler E, Lenney W: Use of budesonide in severe asthmatics aged 1–3 years. Arch Dis Child 1993, 69:351–355.

    PubMed  CAS  Google Scholar 

  15. de Blic J, Delacourt C, Le Bourgeois M, et al.: Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996, 98:14–20.

    Article  PubMed  Google Scholar 

  16. Bisgaard H, Munck SL, Nielsen JP, et al.: Inhaled budesonide for treatment of recurrent wheezing on early childhood. Lancet 1990, 336:649–651.

    Article  PubMed  CAS  Google Scholar 

  17. Kelly HW: Comparison of inhaled corticosteroids. Ann Pharmacother 1998, 32:220–232.

    Article  PubMed  CAS  Google Scholar 

  18. Spahn JD, Leung DTM, Surs W, et al.: Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 1995, 151:1709–1714.

    PubMed  CAS  Google Scholar 

  19. Bisgaard H, Gillies J, Groenewald M, Maden C: The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999, 160:126–131. This is the first large study (n=237) to confirm the clinical efficacy of ICS therapy by MDI with holding chamber and face mask in infants and young children (1 to 4 years of age). Patients received either 100 μg or 200 μg daily of fluticasone propionate or placebo. Both doses produced significant reductions in asthma exacerbations as well as improved symptom scores.

    PubMed  CAS  Google Scholar 

  20. Nielsen KG, Bisgaard H: The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med 2000, 162:1500–1506.

    PubMed  CAS  Google Scholar 

  21. Bisgaard H: Delivery of inhaled medication to children. J Asthma 1997, 34:443–467.

    PubMed  CAS  Google Scholar 

  22. Fink JB: Metered-dose inhalers, dry-powder inhalers, and transitions. Respir Care 2000, 45:623–635.

    PubMed  CAS  Google Scholar 

  23. Hill LS, Slater AL: A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998, 92:105–110.

    Article  PubMed  CAS  Google Scholar 

  24. Devadason SG, Everard ML, MacEarlan C, et al.: Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997, 10:2023–2028.

    Article  PubMed  CAS  Google Scholar 

  25. Wildhaber JH, Dore ND, Wilson JM, et al.: Inhalation therapy in asthma: nebulizer or pressurized meter-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999, 135:28–33. One of only two in vivo radiolabel studies in infants establishing the delivery of nebulized and MDI plus holding chamber. An interesting finding was the delivery to an infant who cried through both delivery methods showing significantly decreased delivery in that infant.

    Article  PubMed  CAS  Google Scholar 

  26. Kelly HW: Aerosol delivery. In Pediatric Asthma. Edited by Murphy S, Kelly HW. New York: Marcel Dekker; 1999. [Lung Biology in Health and Disease Series/126.]

    Google Scholar 

  27. Dolovich MA, MacIntyre NR, Dhand R, et al.: Consensus conference on aerosols and delivery devices. Respir Care 2000, 45:588–776. An entire issue of the journal providing state of the art on the science and clinical relevance of all aspects of aerosol delivery to patients. Although each of the topics covered is excellent, those who care for children will be particularly interested in sections written by Drs. Hess (nebulizers); Fink (MDIs, DPIs); Cole (neonates and pediatrics); and Everard, who wrote a clinician’s perspective. Dr. Everard has made outstanding contributions to the literature on pediatric aerosol delivery over the years and his perspective at the end is well worth reading.

    Google Scholar 

  28. van der Veen MJ, van der Zee JS: Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. Eur Respir J 1999, 13:668–672.

    Article  PubMed  Google Scholar 

  29. Piérart F, Wildhaber JH, Vrancken I, et al.: Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999, 13:673–678.

    Article  PubMed  Google Scholar 

  30. Amirav I, Newhouse MT: Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001, 108:389–394.

    Article  PubMed  CAS  Google Scholar 

  31. Dompeling E, Oudesluys-Murphy AM, Janssens HM, et al.: Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch Dis Child 2001, 84:178–182.

    Article  PubMed  CAS  Google Scholar 

  32. Janssens HM, Heijnen EMEW, de Jong VM, et al.: Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Respir J 2000, 16:850–856.

    Article  PubMed  CAS  Google Scholar 

  33. Everard ML, Clark AR, Milner AD: Drug delivery from holding chambers with attached facemask. Arch Dis Child 1992, 67:580–585.

    Article  PubMed  CAS  Google Scholar 

  34. Pedersen S: Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 2001, 164:521–535. This is an exhaustive review written by the foremost authority on the issue of the effect of ICSs on growth in children. A must for the library of anyone who cares for asthmatic children. It discusses the clinical relevance of the various types of studies on growth from ultra-shortterm studies utilizing knemometry to long-term trials, putting them in useful clinical perspective.

    PubMed  CAS  Google Scholar 

  35. Sharek PJ, Bergman DA: The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000, 106:E8. Available at http://www.pediatrics.org/ cgi/content/full/106/1/e8.

    Article  PubMed  CAS  Google Scholar 

  36. US Food and Drug Administration: Paper presented at the Joint Meeting of the Pulmonary Allergy Drugs and Endocrinologic and Metabolic Drugs Advisory Committees, Bethesda, MD, 1998.

  37. Verberne A, Frost C, Roorda R, et al.: One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997, 156:688–695.

    PubMed  CAS  Google Scholar 

  38. Simons EF: A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997, 337:1659–1665.

    Article  PubMed  CAS  Google Scholar 

  39. Agertoft L, Pedersen S: Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000, 343:1064–1069.

    Article  PubMed  CAS  Google Scholar 

  40. Agertoft L, Pedersen S: Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994, 88:373–381.

    Article  PubMed  CAS  Google Scholar 

  41. Levine LS, Boston BA: Effect of inhaled corticosteroids on the hypothalamic-pituitary axis and growth in children. J Pediatr 2000, 137:450–454.

    Article  PubMed  CAS  Google Scholar 

  42. Allen D, Bronsky E, LaForce C, et al.: Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998, 132:472–477.

    Article  PubMed  CAS  Google Scholar 

  43. Ferguson AC, Spier S, Manjra A, et al.: Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr 1999, 134:422–427.

    Article  PubMed  CAS  Google Scholar 

  44. Lemanske RF, Sorkness CA, Mauger EA, et al.: Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001, 285:2594–2603.

    Article  PubMed  CAS  Google Scholar 

  45. Nelson H: Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001, 107:397–416.

    Google Scholar 

  46. Zeiger RS, Dawson C, Weiss S, et al.: Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999, 103:376–387.

    Article  PubMed  CAS  Google Scholar 

  47. Martinez FD, Wright AL, Taussig LM, et al.: Asthma and wheezing in the first six years of life. N Engl J Med 1995, 332:133–138.

    Article  PubMed  CAS  Google Scholar 

  48. Fuhlbrigge AL, Kitch BT, Paltiel D, et al.: FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001, 107:61–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Children’s Hospital of New Mexico, ACC Building, 3rd Floor, 2211, Lomas Boulevard NE, 87131-5311, Albuquerque, NM, USA

    H. William Kelly PharmD & Hengameh Heidarian- Raissy PharmD

Authors
  1. H. William Kelly PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hengameh Heidarian- Raissy PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelly, H.W., Raissy, H.H. The use of inhaled corticosteroids in children with asthma. Curr Allergy Asthma Rep 2, 133–143 (2002). https://doi.org/10.1007/s11882-002-0008-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-002-0008-z

Keywords

Search

Navigation